

University of Dundee

## Time trends in diagnostic testing for primary ciliary dyskinesia in Europe

Halbeisen, Florian S.; Shoemark, Amelia; Barbato, Angelo; Boon, Mieke; Carr, Siobhan; Crowley, Suzanne

*Published in:*  
European Respiratory Journal

*DOI:*  
[10.1183/13993003.00528-2019](https://doi.org/10.1183/13993003.00528-2019)

*Publication date:*  
2019

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

### *Citation for published version (APA):*

Halbeisen, F. S., Shoemark, A., Barbato, A., Boon, M., Carr, S., Crowley, S., Hirst, R., Karadag, B., Koerner-Rettberg, C., Loebinger, M. R., Lucas, J. S., Maitre, B., Mazurek, H., Özçelik, U., Martinů, V., Schwerk, N., Thouvenin, G., Tschanz, S. A., Yiallourous, P., ... Kuehni, C. E. (2019). Time trends in diagnostic testing for primary ciliary dyskinesia in Europe. *European Respiratory Journal*, 54(4), [1900528].  
<https://doi.org/10.1183/13993003.00528-2019>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# Time trends in diagnostic testing for PCD in Europe

Halbeisen Florian S<sup>1</sup>, Shoemark Amelia<sup>2-3</sup>, Barbato Angelo<sup>4-5</sup>, Boon Mieke<sup>6</sup>, Carr Siobhan<sup>2</sup>, Crowley Suzanne<sup>7</sup>, Hirst Rob<sup>8</sup>, Karadag Bulent<sup>9</sup>, Koerner-Rettberg Cordula<sup>10</sup>, Loebinger Michael R<sup>11</sup>, Lucas Jane S<sup>12</sup>, Maitre Bernard<sup>13-14</sup>, Mazurek Henryk<sup>15</sup>, Özçelik Uğur<sup>16</sup>, Martinů Vendula<sup>17</sup>, Schwerk Nicolaus<sup>18</sup>, Thouvenin Guillaume<sup>13,19-20</sup>, Tschanz Stefan A<sup>21-22</sup>, Yiallourous Panayiotis<sup>23</sup>, \*Goutaki Myrofora<sup>1,24</sup>, \*Kuehni Claudia E<sup>1,24</sup>

\* Both authors contributed equally

## Author affiliations:

1. Institute of Social and Preventive Medicine, University of Bern, Switzerland
2. Department of Paediatrics, Primary Ciliary Dyskinesia Centre, Royal Brompton and Harefield Foundation Trust, London, UK
3. School of Medicine, University of Dundee, Dundee, Scotland
4. for the Italian PCD Consortium
5. Department of Paediatrics, University of Padova, Padova, Italy
6. Department of Paediatrics, University Hospital Gasthuisberg, Leuven, Belgium
7. Unit for Paediatric Heart, Lung, Allergic Diseases, Rikshospitalet, Oslo, Norway
8. Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, Leicester, United Kingdom
9. Department of Pediatric Pulmonology, Marmara University, School of Medicine, Istanbul, Turkey
10. Department of Paediatric Pneumology, University Children's Hospital of Ruhr University Bochum, Germany
11. Host Defence Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
12. Primary Ciliary Dyskinesia Centre, NIHR Respiratory Biomedical Research Centre, University of Southampton, UK
13. on behalf of the French Reference Centre for Rare Lung Diseases
14. Hopital intercommunal de Créteil, Service de Pneumologie, DHU ATVB, Université Paris Est Créteil, France
15. Department of Pneumology and Cystic Fibrosis, Institute of Tuberculosis and Lung Disorders, ul.Prof.Rudnika 3b, 34-700 Rabka - Zdrój, Poland
16. Department of Pediatric Pulmonology, Hacettepe University Faculty of Medicine, Ankara, Turkey
17. Pediatric Department, Charles University Prague and University Hospital Motol, Prague, Czech Republic.
18. Clinic for paediatric pulmonology, allergiology and neonatology, Hannover Medical School, Germany
19. Paediatric Pulmonary Department, Trousseau Hospital APHP, Sorbonne Universities and Pierre et Marie Curie University, Paris, France
20. INSERM U938-CRSA, Paris, France
21. on behalf of the Swiss PCD Group
22. Institute of Anatomy, University of Bern, Bern, Switzerland
23. Medical School, University of Cyprus, Nicosia, Cyprus
24. Paediatric Respiratory Medicine, Children's University Hospital of Bern, University of Bern, Switzerland

Word counts: 1648 / 1500

References: 14 / 15

1  
2  
3 47 *To the Editor:*  
4  
5 48 Despite recent advances in diagnostic methods, diagnosis of primary ciliary dyskinesia (PCD)  
6 49 remains complex. We need a combination of different diagnostic tests, and all have their limitations  
7 50 [1]. In 2009, the first European Respiratory Society Task Force (ERS TF) on PCD in children  
8 51 published recommendations [2], suggesting that: 1) Nasal nitric oxide (nNO) should be measured  
9 52 to screen for PCD in patients aged  $\geq 5$  years [3]; and 2) video microscopy (VM) analysis of ciliary  
10 53 beat pattern and frequency [4] plus electron microscopy (EM) [5] should be the key confirmatory  
11 54 diagnostic tests. Genetic testing was not recommended as part of the initial diagnostic testing, but  
12  
13 55 as additional test for inconclusive cases. The recommended test combination was nNO, VM and  
14  
15  
16 56 EM for patients aged  $\geq 5$  years and VM plus EM for younger patients.  
17  
18  
19 57 In 2017, a second ERS TF on PCD diagnosis revised the accumulated literature and published  
20 58 evidence-based guidelines [6]. Although evidence-based guidelines have become the norm in  
21  
22 59 research, their practical implementation can be challenging [7]. We wanted to assess whether the  
23  
24 60 2009 diagnostic recommendations had been implemented and how diagnosis of PCD changed in  
25 61 Europe over time. This knowledge will help to improve implementation of the new guidelines.  
26  
27  
28 62 We analysed data from the international PCD cohort (iPCD) (details are published elsewhere [8]).  
29  
30 63 By May 2018, iPCD included data on 3733 patients from 26 centres in 21 countries. For this study,  
31  
32 64 we included all datasets from European centres that tested patients with PCD, both before and  
33 65 after 2009, and had complete information on nNO, EM and VM testing. We excluded patients in  
34  
35 66 whom diagnosis was based only on clinical presentation, patients with unknown dates of testing.  
36  
37 67 We included 2108 patients from 16 centres (11 European countries) (Belgium, Cyprus, Czech  
38  
39 68 Republic, France, Germany, Italy, Norway, Poland, Switzerland, Turkey and United Kingdom); 51%  
40 69 were male, 818 patients (39%) had been diagnosed before and 1290 after 2009. All three  
41  
42 70 recommended tests were available in all countries, with the exception of Norway where VM testing  
43 71 was not available neither before nor after 2009.  
44  
45  
46 72 Based on the 2009 recommendations, we only considered nNO measurements in patients aged 5  
47 73 years or older [2]. We considered the nNO test as positive when nNO was below  $77 \text{ nL} \cdot \text{min}^{-1}$   
48  
49 74 [9,10]. VM had been performed with different techniques over time, with high speed video analysis  
50 75 being the most commonly used technique in recent years. We classified VM and EM results as  
51  
52 76 pathological based on information provided by the centres on the beat frequency, beat pattern and  
53 77 cilia ultrastructure. For each patient, we defined the calendar year of diagnosis based on the date  
54  
55 78 of the earliest positive test result. We then assessed whether there was a change over time in the  
56

57 79 proportion of diagnosed patients who had received a) the recommended test combination; b) any  
58 80 single test. We compared the proportion of patients with the recommended test combination (VM  
59  
60

5  
5  
5  
6  
5  
7

and EM for patients aged <5 years and nNO, VM and EM for older patients) for the two time periods, before and after 2009. We used R version 3.1.2 for all analyses.

**Recommended test combination:** Overall, we found no significant trend over time in the use of the test combination. The three tests had been used in 54% of patients diagnosed before 2009 and in 57% after 2009 ( $p=0.15$ ) (Figure 1). In preschool children the proportion diagnosed with the recommended combination was 72% before and 75% ( $p=0.47$ ) after 2009; in older patients it increased from 46% to 52% ( $p=0.03$ ). Results differed between countries. Few countries (e.g. Belgium, Cyprus) combined all 3 tests already before 2009 for most patients and continued to do so after 2009. In Germany, the UK and the Czech Republic, the combined use of all 3 tests was common already before 2009 but increased even more after 2009, with almost  $\frac{3}{4}$  of the patients tested according to recommendations. The remaining countries (Turkey, Switzerland, Italy, France and Poland) showed little or no change over time. In these countries, less than half of the patients, were tested with all 3 approaches even in the later period.

**Nasal NO** testing increased overall from 63% before 2009 to 84% afterwards ( $p<0.001$ ). This increase was seen in most countries (Figure 1). After 2009, nNO was measured in over  $\frac{3}{4}$  of patients in all countries, except in Czech Republic (65%), Italy (70%) and UK (77%).

**Electron microscopy** was frequently performed before 2009 (97%) but decreased to 80% ( $p<0.001$ ) in the later period. Its use became less common in Poland (79% to 69%), Switzerland (88% to 62%) and Turkey (100% to 18%), in all other countries it remained stable or increased after 2009. **Video microscopy** analysis increased overall from 76% to 87% ( $p<0.001$ ). This was mainly because the use of VM for PCD diagnosis increased considerably in Italy (36% to 69%) and Turkey (25% to 88%). In most countries, its use remained stable, while in Switzerland (50% to 21%) it decreased substantially.

This is the first multi-national study that compared diagnostic testing in PCD patients between countries and over time. Although a large number of countries contribute to iPCD, some had to be excluded for this analysis as they only contributed patients diagnosed after 2009 to the iPCD cohort. Thus, our study describes how the consensus recommendations were implemented in 11 countries. They are not representative for all European countries, but only for those with established PCD diagnostic protocols. In this analysis we included both children and adults. However when we limited the analysis to children only, for whom the 2009 recommendations were intended, results remained similar.

Our results suggest that the implementation of the recommended diagnostic combination of nNO, EM and VM testing after the 2009 consensus statement remained low. This reflects the complex nature of PCD diagnostics and the regional resources. Many countries continued to perform only one or two of the recommended tests. There are several explanations for this observation. First,

1  
 2  
 3 116 the availability of local resources could have led to the development of alternative diagnostic  
 4  
 5 117 pathways, which may have been most appropriate for the local situation at that time. All PCD  
 6 118 diagnostic tests need specialised expensive equipment and personnel experienced in analysis of  
 7  
 8 119 VM and EM results, which are not available in all settings. Limited resources or decentralised  
 9 120 healthcare might not have allowed to set up diagnostic centres with scientists experienced in all  
 10  
 11 121 methods. For countries with limited resources cost-effective alternatives for diagnostic testing have  
 12  
 13 122 been suggested, which might provide an acceptable diagnostic accuracy [11]. Second, since 2009  
 14 123 the use of other methods including genetic testing [12,13] and immunofluorescence microscopy  
 15  
 16 124 [14,15] became more widespread. These newer methods might have been used instead of the  
 17 125 recommended tests in some centres. Lastly, the lack of sufficient evidence supporting the use of  
 18  
 19 126 some diagnostic tests in 2009 might have prevented some countries to implement the full set of  
 20  
 21 127 recommended tests but let them to develop their own diagnostic algorithms. We found  
 22 128 considerable heterogeneity between countries in the use of the three tests. Overall, countries with  
 23  
 24 129 low prior use of nNO showed improvement and nNO is now used in most patients aged  $\geq 5$  years  
 25 130 suspected for PCD. For the proportion of patients who were still not tested after 2009, we  
 26  
 27 131 speculate that nNO was not performed as a screening test, and the primary investigators chose to  
 28 132 do directly one or both of the other tests. In this case, if the diagnosis was already established  
 29  
 30 133 based on the results of the other tests, the patients might not have been invited posthoc to perform  
 31  
 32 134 also nNO measurement. This would be in line with the recommendations. We found that use of EM  
 33 135 analysis decreased, and VM increased, suggesting that there might be a shift from EM to VM  
 34  
 35 136 overall. Possible reasons are the realization that a significant proportion of patients have normal  
 36 137 EM findings [16] and the high costs of EM analysis combined with an increased availability of VM,  
 37  
 38 138 so that only patients with inconclusive VM results were referred for EM testing. The overall  
 39  
 40 139 changes in use of VM and EM analyses were strongly affected by the marked increase in VM and  
 41 140 decrease in EM analysis in Turkish patients. This shift is explained by the development of a new  
 42  
 43 141 PCD centre, which uses VM more and EM less frequently.  
 44  
 45 142 The 2009 PCD diagnostic consensus is a typical example of how difficult it is to implement  
 46  
 47 143 guidelines in clinical practice. Even though the recommendations were widely presented in  
 48 144 scientific conferences and meetings, improving knowledge is not sufficient to change daily  
 49  
 50 145 practices. A synthesis of systematic reviews on clinical guideline implementation strategies showed  
 51 146 that passive dissemination was an ineffective measure and that implementation strategies should  
 52  
 53 147 be multifaceted, and actively engage clinicians throughout the process [7]. In the case of PCD  
 54 148 diagnosis, implementation is further hindered by fragmentation of national diagnostic services in  
 55  
 56 149 many centres and the cost of diagnostic equipment. In our study, countries with limited resources  
 57  
 58 150 (e.g. Poland, Turkey) or decentralised diagnosis (e.g. France, Italy, Switzerland) performed the  
 59 151 recommended test combination less frequently, than countries with more resources (e.g. Germany,  
 60  
 152 Belgium, UK) or established centralised PCD diagnosis (e.g. Cyprus, UK). National and multi-

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

153 national collaborations, such as the European Reference Network for respiratory diseases (ERN-  
154 Lung; <https://ern-lung.eu/>) might play an important role, in the future to facilitate centralised  
155 diagnosis and standardised patient care. With the further development and improvement of  
156 diagnostic tests for PCD and with new centres emerging, that might lack the necessary expertise,  
157 there is an increased need for national and international collaboration in PCD diagnostic testing.

158 Overall, we found a low adherence to the 2009 consensus recommendations mainly due to the  
159 decrease in use of EM analysis in some countries. This resulted in low use of the recommended  
160 test combination. To further improve PCD diagnosis, we must be more diligent and engaging in  
161 implementing the new evidence-based guidelines published in 2017, putting more emphasis on  
162 establishing specialised diagnostic centres and close international collaboration.

163

- 1
- 2
- 3
- 4 164 1. Lucas JS, Paff T, Goggin P, Haarman E. Diagnostic Methods in Primary Ciliary Dyskinesia. *Paediatr*
- 5 165 *Respir Rev* 2016;18:8-17.
- 6 166 2. Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Baktai G, Bartoloni L, Eber E, Escribano A,
- 7 167 Haarman E, Hesselmar B, Hogg C, Jorissen M, Lucas J, Nielsen KG, O'Callaghan C, Omran H, Pohunek P,
- 8 168 Strippoli MP, Bush A. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment
- 9 169 approaches in children. *Eur Respir J* 2009;34:1264-76.
- 10 170 3. Lundberg JO, Weitzberg E, Nordvall SL, Kuylensstierna R, Lundberg JM, Alving K. Primarily nasal
- 11 171 origin of exhaled nitric oxide and absence in Kartagener's syndrome. *Eur Respir J*
- 12 172 1994;7:1501-4. 12 172 4. Santamaria F, de Santi MM, Grillo G, Sarnelli P, Caterino M,
- 13 173 Greco L. Ciliary motility at light microscopy: a screening technique for ciliary defects. *Acta*
- 14 174 *Paediatr* 1999;88:853-7.
- 15 175 5. Afzelius BA. A human syndrome caused by immotile cilia. *Science* 1976;193:317-9.
- 16 176 6. Lucas JS, Barbato A, Collins SA, Goutaki M, Behan L, Caudri D, Dell S, Eber E, Escudier E, Hirst RA,
- 17 176 Hogg C, Jorissen M, Latzin P, Legendre M, Leigh MW, Midulla F, Nielsen KG, Omran H, Papon JF,
- 18 177 Pohunek P, Redfern B, Rigau D, Rindlisbacher B, Santamaria F, Shoemark A, Snijders D, Tonia T,
- 19 178 Titieni A, Walker WT, Werner C, Bush A, Kuehni CE. European Respiratory Society guidelines for
- 20 179 the diagnosis of primary ciliary dyskinesia. *Eur Respir J* 2017;49.
- 21 180 7. Grimshaw J, Eccles M, Tetroe J. Implementing clinical guidelines: current evidence and future
- 22 181 implications. *J Contin Educ Health Prof* 2004;24 Suppl 1:S31-7.
- 23 182 8. Goutaki M, Maurer E, Halbeisen FS, Amirav I, Barbato A, Behan L, Boon M, Casaulta C, Clement A,
- 24 183 Crowley S, Haarman E, Hogg C, Karadag B, Koerner-Rettberg C, Leigh MW, Loebinger MR, Mazurek H,
- 25 184 Morgan L, Nielsen KG, Omran H, Schwerck N, Scigliano S, Werner C, Yiallourous P, Zivkovic Z, Lucas
- 26 185 J, Kuehni CE. The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first
- 27 186 results. *Eur Respir J* 2017;49.
- 28 187 9. Collins SA, Gove K, Walker W, Lucas JS. Nasal nitric oxide screening for primary ciliary dyskinesia:
- 29 188 systematic review and meta-analysis. *Eur Respir J* 2014;44:1589-99.
- 30 189 10. Leigh MW, Hazucha MJ, Chawla KK, Baker BR, Shapiro AJ, Brown DE, Lavange LM, Horton BJ, Qaqish
- 31 190 B, Carson JL, Davis SD, Dell SD, Ferkol TW, Atkinson JJ, Olivier KN, Sagel SD, Rosenfeld M, Milla
- 32 191 C, Lee HS, Krischer J, Zariwala MA, Knowles MR. Standardizing nasal nitric oxide measurement
- 33 192 as a test for primary ciliary dyskinesia. *Ann Am Thorac Soc* 2013;10:574-81.
- 34 193 11. Rumman N, Jackson C, Collins S, Goggin P, Coles J, Lucas JS. Diagnosis of primary ciliary dyskinesia:
- 35 194 potential options for resource-limited countries. *Eur Respir Rev* 2017;26.
- 36 195 12. Omran H, Haffner K, Volkel A, Kuehr J, Ketelsen UP, Ross UH, Konietzko N, Wienker T, Brandis M,
- 37 196 Hildebrandt F. Homozygosity mapping of a gene locus for primary ciliary dyskinesia on
- 38 197 chromosome 5p and identification of the heavy dynein chain DNAH5 as a candidate gene. *Am J*
- 39 198 *Respir Cell Mol Biol* 2000;23:696-702.
- 40 199 13. Kim RH, D AH, Cutz E, Knowles MR, Nelligan KA, Nykamp K, Zariwala MA, Dell SD. The role of
- 41 200 molecular genetic analysis in the diagnosis of primary ciliary dyskinesia. *Ann Am Thorac Soc* 2014;11:351-9.
- 42 201 14. Fliegauf M, Olbrich H, Horvath J, Wildhaber JH, Zariwala MA, Kennedy M, Knowles MR, Omran H.
- 43 202 Mislocalization of DNAH5 and DNAH9 in respiratory cells from patients with primary ciliary dyskinesia. *Am J*
- 44 203 *Respir Crit Care Med* 2005;171:1343-9.
- 45 204 15. Shoemark A, Frost E, Dixon M, Ollosson S, Kilpin K, Patel M, Scully J, Rogers AV, Mitchison
- 46 205 HM, Bush A, Hogg C. Accuracy of Immunofluorescence in the Diagnosis of Primary Ciliary
- 47 206 Dyskinesia. *Am J Respir Crit Care Med* 2017;196:94-101.
- 48 207 16. Kouis P, Yiallourous PK, Middleton N, Evans JS, Kyriacou K, Papatheodorou SI. Prevalence of primary
- 49 208 ciliary dyskinesia in consecutive referrals of suspect cases and the transmission electron microscopy
- 50 209 detection rate: a systematic review and meta-analysis. *Pediatr Res* 2017;81:398-405.
- 51 210
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60






Figure 1: Proportion of performed diagnostic tests in European countries before and after the 2009 consensus statement on PCD diagnostics.